Advertisement

Topics

Effect of Therapeutic INR on Activated Clotting Times, Heparin Dosage, and Bleeding Risk During Ablation of Atrial Fibrillation.

06:00 EDT 4th September 2010 | BioPortfolio

Summary of "Effect of Therapeutic INR on Activated Clotting Times, Heparin Dosage, and Bleeding Risk During Ablation of Atrial Fibrillation."

Effect of INR on Anticoagulation During Ablation of Atrial Fibrillation. Background: Ablation of atrial fibrillation (AF) with international normalized ratio (INR) >/= 2.0 is safe and may reduce thromboembolic complications. Heparin is administered during the procedure, but the effect of elevated INR on heparin requirements and target activation clotting times (ACT) >/= 350 seconds during ablation is unknown. Objectives: To study the effect of INR on intraprocedural anticoagulation during ablation of AF. Methods: We retrospectively studied 427 consecutive patients over an 18-month period when we were transitioning to continuation of warfarin for AF ablation. Baseline INR, procedural ACT measurements, heparin doses and major complications were analyzed according to Group 1 with INR < 2.0 (n = 246) and Group 2 with INR >/= 2.0 (n = 181). Results: In Group 1, the mean INR was lower (1.3 +/- 0.3 s vs 2.4 +/- 0.3; P < 0.001), and the mean heparin dose was greater (106.82 +/- 40.01 vs 77.03 +/- 18.5 U/kg; P < 0.001). A single heparin bolus achieved ACT >/= 350 seconds throughout the procedure in 51 patients (20.7%) in Group 1 compared to 108 patients (59.7%) in Group 2 (P < 0.01). Mean ACT values were higher in Group 2. Symptomatic pericardial effusions were similar (2.4% in Group 1 and 2.2% in Group 2). There were 3 thromboembolic cerebrovascular events in Group 1 and none in Group 2. Femoral hematomas occurred more frequently in Group 1 (8.1%) than in Group 2 (3.3%) (P = 0.007). Conclusions: AF ablation with INR >/= 2.0 provides a consistent anticoagulant milieu during the procedure, with lower heparin requirements that are important to anticipate. (J Cardiovasc Electrophysiol, Vol. pp. 1-7).

Affiliation

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Journal Details

This article was published in the following journal.

Name: Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Pages:

Links

DeepDyve research library

PubMed Articles [25375 Associated PubMed Articles listed on BioPortfolio]

Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children.

Bivalirudin, a direct thrombin inhibitor, is a useful alternative to heparin for anticoagulation in infants and children. It has been found to be effective in patients requiring treatment of thrombosi...

The Use of Heparin during Endovascular Peripheral Arterial Interventions: A Synopsis.

A large variety exists for many aspects of the use of heparin as periprocedural prophylactic antithrombotics (PPAT) during peripheral arterial interventions (PAI). This variation is present, not only ...

Novel method using rotational thromboelastography analysis for intraoperative management of device patient with heparin-induced thrombocytopenia.

Heparin-induced thrombocytopenia (HIT) is a prothrombotic disease in response to previous heparin exposure. Direct thrombin inhibitors are suitable candidates for the prophylaxis of thrombosis in pati...

Prevalence Of "Flat-Line" Thromboelastography During Extracorporeal Membrane Oxygenation For Respiratory Failure In Adults.

We evaluated the prevalence of a thromboelastography reaction time (R time) > 90 minutes ("flat-line") reversible with heparinase during Extracorporeal Membrane Oxygenation (ECMO). We evaluated the as...

The toxicology of heparin reversal with protamine: past, present and future.

Unfractionated heparin is a strongly anionic anticoagulant used extensively in medicine to prevent blood clotting. In the case of an emergency bleeding in response to heparin, the antidote is protamin...

Clinical Trials [4621 Associated Clinical Trials listed on BioPortfolio]

Adjusted Calculation of Heparin and Protamin Dosing and Correlation With Postoperative Bleeding and Transfusions

The study will compare a novel calculation model (HeProCalc AB) with a standard weight-based and activated clotting time adjusted calculation for the dosing of Heparin and protamine and as...

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

Primary Objective: To assess the safety of bivalirudin as an alternative anticoagulant therapy for patients with new or previous heparin-induced thrombocytopenia (HIT) / heparin-induced ...

Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome

The purpose of this study is to determine which of these anti-clotting medications, abciximab plus unfractionated heparin or bivalirudin, is more effective to prevent thrombotic and bleedi...

Cardiac Surgery: In Vivo Titration of Protamine

Safe use of cardiopulmonary bypass (CPB) requires massive doses of intravenous unfractionated heparin. At end-CPB, residual heparin is neutralized with intravenous injection of protamine s...

Heparin Based on Ideal Body Weight for Cardiopulmonary Bypass in Obese Patients

The optimal heparin regimen during cardiopulmonary bypass (CPB) has not been well established in obese patients. Results of a preview study show that the standard heparin management based...

Medical and Biotech [MESH] Definitions

The highest dosage administered that does not produce toxic effects. The NOAEL will depend on how closely dosages are spaced (lowest-observed-adverse-effect level and no-observed-effect level) and the number of animals examined. The ultimate objective is usually to determine not the "safe" dosage in laboratory animals but the "safe" dosage for humans. Therefore, the extrapolation most often required of toxicologists is from high-dosage studies in laboratory animals to low doses in humans. (Casarett and Doull's Toxicology: The Basic Science of Poisons, 4th ed)

A proteolytic enzyme obtained from the venom of fer-de-lance (Bothrops atrox). It is used as a plasma clotting agent for fibrinogen and for the detection of fibrinogen degradation products. The presence of heparin does not interfere with the clotting test. Hemocoagulase is a mixture containing batroxobin and factor X activator. EC 3.4.21.-.

Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.

A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

A sulfated plasma protein with the MW of approximately 66kDa that resembles ANTITHROMBIN III. The protein is an inhibitor of thrombin in plasma and is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily.

Quick Search
Advertisement
 


DeepDyve research library

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...